Physician profile
Daniel Deprince
NPI 1023080306
$1,023.71
in general payments reported to CMS, 2019-2025
19 companies · $44.06 in 2025
The $44.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $813 · 2022: $127 · 2024: $39.36 · 2025: $44.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $83.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $83.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $273.49 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $105.81 | 2019 | |
| Zimmer Biomet Holdings, INC. | $104.03 | 2019 | |
| Ethicon US, LLC | $79.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $60.66 | 2019 | |
| Pfizer INC. | $58.70 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $53.27 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $50.93 | 2019 | |
| Amarin Pharma, INC. | $43.55 | 2019 | |
| Lilly USA, LLC | $39.77 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.96 | 2019 | |
| Merck Sharp & Dohme LLC | $28.03 | 2019 | |
| Astellas Pharma US INC | $20.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.75 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $13.05 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.02 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Deprince listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.